|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Biomarker Analyses of Response to Cyclin Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women With Treatment-Naïve Metastatic Breast Cancer.
|
31527167 |
2020 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Three CDK4/6 inhibitors, including palbociclib (PD0332991), ribociclib (LEE011) and abemaciclib (LY2835219), have been approved by the US Food and Drug Administration (FDA) for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
|
31632494 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
CDK4/6 inhibitors are used to treat estrogen receptor (ER)-positive metastatic breast cancer (BC) in combination with endocrine therapy.
|
30523750 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, these findings suggest that while <i>FGFR1</i> amplification confers broad resistance to ER, PI3K, and CDK4/6 inhibitors, mTOR inhibitors might have a unique therapeutic role in the treatment of patients with ER<sup>+</sup>/FGFR1<sup>+</sup> MBC.
|
31371343 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the pharmacologic costs of CDK4/6 inhibitors (palbociclib and ribociclib) in hormone receptor-positive (HR<sup>+</sup>)/human epidermal receptor 2-negative (HER2<sup>-</sup>) advanced or metastatic breast cancer (BC).
|
30858036 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
PI3K/mTOR/CDK4/6 inhibitors may influence the development of edema, which may cause or exacerbate progression of BCRL in patients with MBC.
|
30919166 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
CDK4/6 inhibitors are a new class of anticancer drugs used for the treatment of women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.
|
30685576 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Three CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) are available for women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.
|
31369120 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Standard treatment for estrogen receptor-positive metastatic breast cancer involves antiestrogen therapy used alone or in combination with inhibitors of CDK4/6 or mTOR; this approach works mechanistically by eliciting and reinforcing cell-cycle arrest.
|
30824486 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the early toxicity of concurrent use of radiotherapy in association with CDK4/6 inhibitors (palbociclib or ribociclib) in patients with hormone-receptors positive metastatic breast cancer.
|
31100573 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in combination with endocrine-therapy have emerged as an important regimen of care for estrogen receptor (ER)-positive metastatic breast cancer, although identifying predictive biomarkers remains a challenge.
|
30692100 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cyclin-dependent kinases 4 and 6 (CDK4/6) are key regulators of the cell cycle, and there are FDA-approved CDK4/6 inhibitors for treating patients with metastatic breast cancer.
|
30802347 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.
|
31346846 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
To describe the clinical role of CDK 4/6 inhibitors in hormone receptor-positive (HR+) metastatic breast cancer (HR+ MBC) as well as current controversies and evolving areas of research.
|
30806829 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> Despite encouraging pre-clinical evidence, there is a lack of clinical data to inform CNS-specific response rates to CDK4/6 inhibitors among patients with metastatic breast cancer.
|
31695840 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Indeed, CDK4/6 inhibitors are currently approved in combination with endocrine therapy for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
|
31647925 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
We pooled data from three randomized controlled studies (N = 1,827) of different CDK4/6 inhibitors in combination with an AI for initial treatment of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer.
|
31560580 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sequential endocrine treatment in monotherapy or in combination with CDK 4/6 or m-TOR inhibitors is the mainstay of recommended treatment options in the management of metastatic breast cancer even in the presence of visceral metastasis.
|
31335829 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we analyze the PI3K/AKT/mTOR and CDK4/6 pathways and their roles in endocrine resistant metastatic breast cancer.
|
31450618 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
CDK 4/6 inhibitors have given patients with estrogen receptor (ER)-positive/HER2-negative (ER+/HER2ࢤ) advanced metastatic breast cancer important new therapeutic options.
|
31464525 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ribociclib is a CDK4-6 inhibitor recently approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as first-line treatment for metastatic breast cancer (MBC).
|
30118901 |
2018 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expert opinion: All three CDK4/6 inhibitors have shown remarkable efficacy when added to endocrine therapy in the treatment of HR+/HER2- MBC with consistent improvements in progression-free survival across all phase III trials.
|
30360668 |
2018 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phase III randomized clinical trials have proven that CDK4/6 inhibitors (CDK4/6i) in combination with several endocrine agents improve treatment efficacy over endocrine agents alone for hormone receptor positive (HR+) HER2 negative (HER2-) metastatic breast cancer (MBC).
|
30631751 |
2018 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expert commentary: CDK4/6 inhibition represents a promising treatment option for patients with HR+ metastatic breast cancer.
|
29457921 |
2018 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Palbociclib, a CDK4-6 inhibitor, combined with endocrine therapy (ET) is a new standard of treatment for Hormone Receptor-positive Metastatic Breast Cancer.
|
29247442 |
2018 |